Background: Recent progress in genomic analysis using next-generation sequencing (NGS) has enabled the comprehensive detection of targetable alterations in non-small cell lung cancer (NSCLC) patients. As the detection of ALK gene fusions is being established by NGS, identification of concurrent alterations will lead to better characterization of the molecular landscape of ALK-rearranged patients. Conclusion: We have studied the presence of ALK fusion genes with a novel NGS panel that showed excellent correlation with standard techniques. ALK fusions can be interpreted as early strong drivers to carcinogenesis due to the low frequency of concurrent alterations. It remains to determine the clinical impact of these alterations in larger series. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.1061
Authors: S. Clavé, M. Salido, J. Gibert, M. Hardy-Werbin, E. Weingartner, J. Hernandez, D. Nichol, P. Rocha, X. Riera, R. Blanco, J. Bosch-Barrera, Á. Taus, L. Pijuan, B. Bellosillo, E. Arriola
